Received PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry and venture capital. Since 1992 has been working in the United States and Europe. Over the recent years Alexey was involved in starting several biotech companies in the US and Europe where he was developing innovative pharmaceutical drugs in different therapeutic areas. Conducted scientific research in the universities in Germany and the US. In 1995-2000 worked as professor at the department of Medicinal Chemistry, University at Buffalo. Was Chief Technology Officer of Alantos and President of its US division. Alantos was acquired by Amgen in 2007 for $300 million. Since 2009 Alexey has been working with the Maxwell Biotech Group as its Managing Director and the head of its Boston office and has managed numerous deals with portfolio companies in the US and Europe.  

NeuroMax develops 2 pharmaceuticals which are in the phase clinical trials:BNV-222 and AQU-005.